About 180 people will get brain scans while choosing between food and money, to see if GLP-1 use dulls the pull of instant rewards.
Recap by typeshit. Full story at KTVH.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Venkat, who works as an ER physician, says dropping GLP-1 coverage for obesity only moves the cost to pricier medical problems later.
The work looks at whether these drugs change impulsive money decisions, not just appetite. No results have been shared yet.
Loading…